Slide 1: Letter to stock exchanges: Investor/Analysts Presentation
AUROBINDO February 10, 2021 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Sandra Kurla Complex, Sandra (E), Phiroz Jeejeebhoy Towers, MUMBAI ·400 051 25th floor, Dalal Street, MUMBAI ·400 001 Company Code No. AUROPHA
Slide 2: Aurobindo Pharma Ltd Earnings Presentation February 2021
AUROBINDO PHARMA LTD Earnings Presentation February 2021
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma, nor shall it, or any part hereof
Slide 4: Index
Index Q3FY21 Business & Financial Highlights 01 Financial Performance 02 Speciality Pipeline & Key Focus Areas 03 Filing Snapshot 04
Slide 5: Q3FY21 Business & Financial Highlights
1 Q3FY21 Business & Financial Highlights
Slide 6: Consolidated Financial Performance – Q3 FY21
Consolidated Financial Performance – Q3 FY21 In Rs Cr Revenue EBITDA Adjusted Profit After Tax* 8.0% YoY 13.3% YoY 16.9% YoY 20.5% 21.5% EBITDA Margin *Net profit after JV share, minority interest excluding exceptional items (net of tax)
Slide 7: Consolidated Financial & Business Highlights – Q3 FY21
Consolidated Financial & Business Highlights – Q3 FY21 Revenue from operations at Rs. 6,364.9 crore, witnessed a growth of 8.0% YoY EBIDTA before Forex and Other income at Rs. 1,368.6 crore, an increase of 13.3% YoY; EBITDA margin is at 21.5% Net Profit after JV share, minority interest at Rs. 2,946
Slide 8: Consistent Quarterly Performance
Consistent Quarterly Performance Revenue (Rs Cr) US Revenue ($ Mn) Natrol US sales Ex Natrol 418 430 431 404 413 412 387 41 41 38 56 353 39 51 339 39 29 40 364 377 376 374 390 348 361 299 324 Q3FY19 Q4FY19 Q1FY20 Q2FY20 Q3FY20 Q4FY20 Q1FY21 Q2FY21 Q3FY21 EBITDA (Rs Cr) Net Debt to Equity* *At the en
Slide 9: US Business Performance Highlights
US Business Performance Highlights Revenue (Rs Cr) Revenue Mix - 9MFY21 2,969 3,190 3,172 415 300 291 Total Injectables 2,872 20.4%% 2,679 2,775 Q3FY20 Q2FY21 Q3FY21 US Sales Ex Natrol Natrol US Formulations • Natrol business was divested during the quarter • US revenue in Q3FY21 witnessed a growth
Slide 10: Europe, ARV, Growth Markets, API Business Performance Highlights
Europe, ARV, Growth Markets, API Business Performance Highlights Europe Revenues Growth Markets Revenues* ARV Revenues API Revenues** 829 1,671 446 503 790 396 682 443 1,476 1,515 346 313 Q3FY20 Q2FY21 Q3FY21 Q3FY20 Q2FY21 Q3FY21 Q3FY20 Q2FY21 Q3FY21 Q3FY20 Q2FY21 Q3FY21 • Europe revenue in Q3FY21 i
Slide 11: Financial Performance
{ 2] AUROBINDO Financial Performance
Slide 12: Consolidated Financial Performance
Consolidated Financial Performance Rs Cr Q3FY21 Q3FY20 (%) Chg Q2FY21 (%) Chg Revenue from operations 6,364.9 5,895.0 8.0 6,483.4 -1.8 Gross Profit 3,792.6 3,330.0 13.9 3,967.7 -4.4 Gross Margin 59.6% 56.5% 61.2% Overheads 2,424.1 2,122.0 14.2 2,534.9 -4.4 EBITDA (before forex and other income) 1,36
Slide 13: Financial Performance – 5 Year trend
Financial Performance – 5 Year trend Rs. Cr FY16 FY17 FY18 FY19 FY20 Revenue 13,955 15,090 16,500 19,564 23,099 Gross Profit 7,793 8,656 9,747 10,851 13,363 Gross Profit Margin 55.8% 57.4% 59.1% 55.5% 57.9% EBITDA 3,188 3,434 3,789 3,952 4,864 EBITDA Margin 22.8% 22.8% 23.0% 20.2% 21.1% Net Profit 2
Slide 14: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (Rs Crore) Mar-18 Mar-19 Mar-20 Sep-20 Dec-20 Closing Rate1 US$ = INR 65.17 69.155 75.6650 73.770 73.07 731 1,006 733 668 680 Fx Loan restated in INR 4,766.9 6,959.0 5,549.2 4,888.1 4,970.6 Rupee Loan 4.1 8.1 16.9 100 114.4 Gross Debt 4,771.0 6,967.1 5,566.1 4,
Slide 15: Drivers for Sustainable Growth – Speciality Pipeline & Key Focus Areas
3 Drivers for Sustainable Growth – Speciality Pipeline & Key Focus Areas
Slide 16: Building a Diverse and Robust Specialty Products Portfolio - Biologics
Building a Diverse and Robust Specialty Products Portfolio - Biologics • CuraTeQ Biologics will continue on the promise of developing biosimilars with a portfolio of products covering market size of over US$ 50 billion • We are focusing our development efforts in four therapeutic areas: Oncology, Im
Slide 17: Vaccines: Creating Access to Affordable Vaccines
Vaccines: Creating Access to Affordable Vaccines Aurobindo’s vaccines pipeline consists of bacterial and viral vaccines • Company is developing PCV vaccine through its Joint Venture with Tergene biotech • Company is developing viral vaccines in Hyderabad and through its wholly-owned step down subsid
Slide 18: Injectables: Broadening the portfolio and reach
Injectables: Broadening the portfolio and reach • Presence in injectables across delivery systems such as liquid & lyophilized vials, bag, ampoules, pre- Injectable ANDAs status filled syringes • Strong manufacturing and execution capabilities • 5 state-of-art manufacturing facilities inspected by v
Slide 19: Rejuvenated focus on API
Rejuvenated focus on API • 11 state-of-the-art API and intermediates manufacturing facilities inspected by the US FDA, UK Unit XI MHRA, TGA Australia, ANVISA and other regulatory agencies; Expanding capacities to further increase supplies to external parties • Business is supported by technologicall
Slide 20: Filing Status
r ) AUROBIN DO alihter lif Filing Status
Slide 21: US Filings Snapshot as on 31st Dec 2020
US Filings Snapshot as on 31st Dec 2020 ANDA Filings Addressable Therapy ANDAs Market Size (US$ Bn) Non - Injectables CNS 108 23.3 Injectables CVS 92 30.5 ARV** 41 3.5 Gastroenterological 35 3.3 SSP & Cephs 31 0.6 Oncology & 41 13.4 Hormones Anti Diabetic 22 20.4 Unit wise ANDA Filings Controlled 15
Slide 22: Filing details
Aurobindo Pharma Limited – Internal Presentation 21 Filing details As at As at As at As at As at As at As at Category Approvals Mar 15 Mar 16 Mar 17 Mar 18 Mar 19 Mar 20 Dec 20 Formulations US* 376 398 429 478 541 586 634 463 (FA: 434, TA:29) 2,680 Dossiers (306 Europe** 1,756 2,224 2,521 2,848 3,00
Slide 23: Thank You
Thank You Investors Contact Investor Relations team ir@aurobindo.com 040-66725401